RT Journal Article
SR Electronic
T1 Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.09.22272113
DO 10.1101/2022.03.09.22272113
A1 Bolze, Alexandre
A1 Basler, Tracy
A1 White, Simon
A1 Rossi, Andrew Dei
A1 Wyman, Dana
A1 Roychoudhury, Pavitra
A1 Greninger, Alexander L.
A1 Hayashibara, Kathleen
A1 Beatty, Mark
A1 Shah, Seema
A1 Stous, Sarah
A1 Kil, Eric
A1 Dai, Hang
A1 Cassens, Tyler
A1 Tsan, Kevin
A1 Nguyen, Jason
A1 Ramirez, Jimmy
A1 Carter, Scotty
A1 Cirulli, Elizabeth T.
A1 Barrett, Kelly Schiabor
A1 Washington, Nicole L.
A1 Belda-Ferre, Pedro
A1 Jacobs, Sharoni
A1 Sandoval, Efren
A1 Becker, David
A1 Lu, James T.
A1 Isaksson, Magnus
A1 Lee, William
A1 Luo, Shishi
YR 2022
UL http://medrxiv.org/content/early/2022/03/28/2022.03.09.22272113.abstract
AB Between November 2021 and February 2022, SARS-CoV-2 Delta and Omicron variants co-circulated in the United States, allowing for co-infections and possible recombination events. We sequenced 29,719 positive samples during this period and analyzed the presence and fraction of reads supporting mutations specific to either the Delta or Omicron variant. We identified 18 co-infections, one of which displayed evidence of a low Delta-Omicron recombinant viral population. We also identified two independent cases of infection by a Delta-Omicron recombinant virus, where 100% of the viral RNA came from one clonal recombinant. In the three cases, the 5’-end of the viral genome was from the Delta genome, and the 3’-end from Omicron including the majority of the spike protein gene, though the breakpoints were different. Delta-Omicron recombinant viruses were rare, and there is currently no evidence that Delta-Omicron recombinant viruses are more transmissible between hosts compared to the circulating Omicron lineages.Competing Interest StatementA.B., T.B., S.W., A.D.R., D.W., E.K., H.D., T.C., K.T., J.N., J.R., S.C., E.T.C., K.S.B., N.L.W., P.B., S.J., E.S., D.B., J.T.L., M.I., W.L., and S.L. are all employees of Helix.Funding StatementThis work has been supported by the Centers for Disease Control and funded in part by CDC Contract 75D30121C12730 (Helix). We also thank the NIH RADx initiative, which funded a portion of this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Helix data analyzed and presented here were obtained through IRB protocol WIRB#20203438, which grants a waiver of consent for a limited dataset for the purposes of public health under section 164.512(b) of the Privacy Rule (45 CFR 164.512(b)). All samples were de-identified before receipt by the study investigators.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. SARS-CoV-2 sequences have been uploaded on GISAID. BAM files have been uploaded to SRA Bioproject: PRJNA804575